232 related articles for article (PubMed ID: 37752541)
21. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
22. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
23. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
24. Tertiary lymphoid structures associated with enhanced anti-tumor immunity and favorable prognosis in cervical squamous carcinoma.
Xiong G; Shan J; Chong Q; Cui Y
Aging (Albany NY); 2024 Apr; 16(8):6898-6920. PubMed ID: 38709170
[TBL] [Abstract][Full Text] [Related]
25. Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Petroni G; Pillozzi S; Antonuzzo L
Cancer Res; 2024 Apr; 84(8):1199-1209. PubMed ID: 38381540
[TBL] [Abstract][Full Text] [Related]
26. Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC.
Devi-Marulkar P; Fastenackels S; Karapentiantz P; Goc J; Germain C; Kaplon H; Knockaert S; Olive D; Panouillot M; Validire P; Damotte D; Alifano M; Murris J; Katsahian S; Lawand M; Dieu-Nosjean MC
Commun Biol; 2022 Dec; 5(1):1416. PubMed ID: 36566320
[TBL] [Abstract][Full Text] [Related]
27. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
Mazzaschi G; Leonetti A; Minari R; Gnetti L; Quaini F; Tiseo M; Facchinetti F
Curr Treat Options Oncol; 2021 Sep; 22(11):96. PubMed ID: 34524570
[TBL] [Abstract][Full Text] [Related]
28. The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer.
Maoz A; Dennis M; Greenson JK
Front Immunol; 2019; 10():1884. PubMed ID: 31507584
[TBL] [Abstract][Full Text] [Related]
29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
30. CD20
Wu Z; Zhou J; Xiao Y; Ming J; Zhou J; Dong F; Zhou X; Xu Z; Zhao X; Lei P; Huang T
Front Immunol; 2022; 13():865596. PubMed ID: 35634306
[TBL] [Abstract][Full Text] [Related]
31. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
32. Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy.
Lin L; Hu X; Zhang H; Hu H
Front Immunol; 2019; 10():1398. PubMed ID: 31281318
[TBL] [Abstract][Full Text] [Related]
33. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC
Front Immunol; 2021; 12():698604. PubMed ID: 34276690
[TBL] [Abstract][Full Text] [Related]
35. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
Tang H; Qiu X; Timmerman C; Fu YX
Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
[TBL] [Abstract][Full Text] [Related]
36. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
37. Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y; Wu Y; Yan G; Zhang G
Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
[TBL] [Abstract][Full Text] [Related]
38. Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer.
Liu R; Huang X; Yang S; Du W; Chen X; Li H
Front Immunol; 2024; 15():1364506. PubMed ID: 38571938
[TBL] [Abstract][Full Text] [Related]
39. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
Front Immunol; 2021; 12():793964. PubMed ID: 34987518
[TBL] [Abstract][Full Text] [Related]
40. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]